MPE gives feedback on the proposed implementing act supporting the EU Health Technology Assessment regulationAccess, MPEApril 8, 2024
Sign up for the MPE webinar “AL amyloidosis treatment updates and patient experiences on new therapies”AL amyloidosis, MPEMarch 27, 2024
Snežana Doder, young myeloma patient: “When I talk about my journey, I compare it to a roller coaster. Everything happened very fast and unexpectedly”MPE, MyelomaMarch 25, 2024
European Commission grants final approval for CAR-T treatment idecabtagene vicleucel (Abecma) in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaMarch 21, 2024
Ana Rocha, young myeloma patient: “I didn’t let the diagnosis change me and I thought I should build something to help others newly diagnosed”MPE, MyelomaMarch 8, 2024
EMA CHMP gives positive recommendation on CAR T-cell therapy ciltacabtagene autoleucel in earlier lines of therapy for relapsed and refractory myelomaAccess, MyelomaFebruary 23, 2024
US FDA approves bi-weekly teclistamab dosing in relapsed/refractory myelomaAccess, MPE, MyelomaFebruary 22, 2024
AMEN provides medical information for Arabic speakers in Israel and beyondAccess, MPEFebruary 13, 2024